I-Cimzia iyisitoreji se-TNF esisetshenziselwa isifo samathambo esivuthayo
I-Cimzia (certolizumab pegol) i- blocker ye- TNF (isifo se-tumor necrosis factor) -isigaba esifanayo semithi njenge- Enbrel (etanercept) , Remicade (infliximab) , i- Humira (adalimumab) , ne-Simponi (golimumab). I-Cimzia yiyona kuphela izidakamizwa ekilasini le-TNF elithinta ukuba ngaphansi kobuhlungu emangqamuzaneni ngenxa yamakhemikhali awo (isibonelo, i-PEGylated, iFc yesifunda samahhala). Ngaphezu kwalokho, uma kuqhathaniswa nezinye izivimbela ze-TNF, kuthiwa i-Cimzia inokubambisana okukhulu kwe-TNF yabantu.
Kuyini i-TNF?
Kuyasiza ukwazi ukuthi i-TNF yenzani ukuze ukwazi ukuthi kungani uCimzia esebenza ukuyivimbela. I-TNF iyi- cytokine , ngokuyisisekelo isithunywa se-molecule phakathi kwamaseli, adlala indima enkambisweni yokuvuvukala . Ukukhiqizwa okungaphezu kwe-TNF-alpha ngomzimba kuye kwaxhunyaniswa nezifo eziningana nezimo, kuhlanganise nesifo samathambo .
I-Cimzia Inikelwe Kanjani?
I-Cimzia ifakwe ngaphansi kwesikhumba. Ihlinzekwa njenge-powder okumele ibuyiswe kabusha ekufakweni kwamanzi ukuze ihlinzekwe njengemjovo engaphansi.
Umenzi wayo, u-UCB, Inc., wathi izimpahla zamakhemikhali ezihlukile zeCimzia zingenza kube ngcono kunezinkinga ezikhona ze-TNF zeziguli zamasosha e-rheumatoid arthritis. Ukwenza kwalo kunganciphisa ukusabela okubi okuhlobene nomjovo kanye nokulethwa kwezidakamizwa kumasayithi okuvuvukala kungathuthukiswa, okudinga ukulingana okuncane kakhulu kunamanye amagciwane.
Ngemuva kwesilinganiso sokuqala, kunesimiso sokuziphendulela nezimo eziguquguqukayo.
I-Cimzia inganikwa ngezikhathi zamasonto amabili noma amane-kungaba yedwa noma nge-methotrexate.
Ukusebenza kwe-Cimzia ekuvivinyweni koMtholampilo
Imiphumela yokuhlolwa komtholampilo enhle yabika i-Cimzia. Izifundo ezimbili zesigaba III zabonisa inzuzo enkulu uma uCimzia esetshenziswa yedwa noma ehlanganiswa ne-methotrexate kubantu abadala abane-arthritis esebenzayo (isib., I- synovitis esebenzayo ).
Ngokuqondile, isifundo se-FAST4WARD seviki ezingama-24 sibonise ukuthi i-400 mg ye-Cimzia, eyanikezwa onke amaviki angu-4 ngaphansi komzimba, iyanciphisa kakhulu ubuhlungu kanye nezibonakaliso nezimpawu zesifo samathambo kanye nomsebenzi owenziwe ngcono uma kuqhathaniswa nalabo abasendaweni ye-placebo.
Ucwaningo lwe-RAPID lwembula inzuzo yokusebenzisa i-Cimzia kanye ne-methotrexate. I-RAPID1 ibonise inzuzo yesikhathi eside ekusebenziseni i-Cimzia ngokwemikhakha yokuphumula, ukuthuthukisa umkhiqizo kanye nekhwalithi yokuphila, nokunciphisa ukukhathala. Ucwaningo lwesibini lwe-RAPID, owaziwa ngokuthi i-RAPID2, lubonise ukuthi i-Cimzia kanye ne-methotrexate izimpawu eziphuthumayo kakhulu zezimpawu ze-rheumatoid arthritis, ukuguqulwa kwesifo, nokusebenza komzimba okuthuthukisiwe kwiziguli ezine-arthritis esebenzayo.
Imiphumela ye-Cimzia Side Effects
Imiphumela emibi kakhulu yenzeke kwabanye abantu abathatha uCimzia. Ukubeka ulwazi olutholakalayo kuCimzia luxwayisa ngokuthi:
- Izifo ezinzima, kuhlanganise nesifo sofuba
- I-Cancer, kuhlanganise ne-lymphoma
- Izinkinga zesimiso sezinzwa, kuhlanganise ne- multiple sclerosis
- Ukuphendula kwe-allergen
- Izinkinga zegazi
- Ukuhluleka kwenhliziyo okusha noma okubi
- Ukusabela kwamagciwane, kuhlanganise ne-lupus-like syndrome
Imiphumela emibi ejwayelekile ehambisana neCimzia yizifo ezingaphezulu zokuphefumula, izifo ezibangelwa umchamo, ubuhlungu obuhlangene, kanye nokuphendula kwesayithi.
Ingabe i-Cimzia FDA-Iyavunyelwa?
Ngo-Ephreli 22, 2008, uCimzia wayevunyelwe i-FDA ukuphatha ngokulinganayo isifo sikaCrohn esicindezelayo kubantu abadala abangazange basizwe ngemithi yokwelapha evamile. Ngo-May 14, 2009, i-Cimzia yamukelwa yi-FDA ukuphatha iziguli ezikhulile ezinezifo ezinomthelela okhuthele kakhulu we-rheumatoid arthritis. Izinkomba zengeziwe nge- psoriatic arthritis kanye ne- ankylosing spondylitis .
I-Cimzia itholakale kwisirinji esandulele ephethe i-Arthritis Foundation's Ease-of-Use Commendation. I-design ye-syringe yimbangela yobambiswano phakathi kwe-UCB no-OXO (eyaziwa kakhulu ngomugqa wabo wezinto zokupheka ze-ergonomic namanye amathuluzi angasebenzisa umsebenzisi).
Imithombo:
Cimzia. Ulwazi lokuPhelela okugcwele. UCB. Kubuyekezwe ngo-Ephreli 2016.
http://www.cimzia.com/assets/pdf/Prescribing_Information.pdf
Cimzia. Umhlahlandlela Wezokwelapha. UCB, Inc. Kubuyekezwe ngo-Ephreli 2016.
http://www.cimzia.com/assets/pdf/MedicationGuide.pdf